Medical/Pharmaceuticals

BGI Genomics obtains BSI ISO 37301 Compliance Management System Certification

HONG KONG, June 30, 2023 /PRNewswire/ -- As businesses become increasingly global, changes are happening at an extraordinary pace. Compliance is critical for large economies, industry regulations, and enterprise operations. BGI Genomics prioritizes compliance management and strictly follows law...

2023-06-30 08:37 4245

Cresilon Receives First FDA Clearance For Human Use of Hemostatic Gel Technology

NEW YORK, June 29, 2023 /PRNewswire/ -- Cresilon, Inc. ("Cresilon"), a Brooklyn -based biotechnology company focused on hemostatic medical device technologies, today announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for Cresilon Hemostatic Gel™ ...

2023-06-29 20:00 2659

CPHI & PMEC China 2023 to launch international roadshow in Guangzhou

China's booming Pearl River Delta, a key pharma manufacturing hub, sees rapid internationalisation SHANGHAI, June 29, 2023 /PRNewswire/ -- CPHI & PMEC China will open a special roadshow to be hosted at the PWTC Expo (4-6 September, 2023) in the city of Guangzhou (Guangdong Province). The new add...

2023-06-29 18:10 3323

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

New state-of-the-art facility to develop immunotherapy assets to address unmet needs in cancer treatment SINGAPORE, June 29, 2023 /PRNewswire/ -- Biosyngen, an immune-oncology company with technology targeting the unmet medical needs in solid tumour and lymphoma treatment, today announced the of...

2023-06-29 17:14 5039

Berlin Heals Holding AG Successfully Completes Financing Round for Ongoing CE-Study

ZUG, Switzerland, June 29, 2023 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech startup, has developed a breakthrough method and a product for the therapy of heart failure. The product - an electronic device called C-MIC - has already successfully been tested in patients in a pilot study and i...

2023-06-29 17:00 3548

Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate That Could Be the First in 100 Years If Proven Effective

TB is one of the world's deadliest diseases, killing about 4,300 people per day, mostly those living in poverty  LONDON and SEATTLE, June 29, 2023 /PRNewswire/ -- Wellcome and the Bill & Melinda Gates Foundation today announced funding to advance a tuberculosis (TB) vaccine candidate, M72/AS01E ...

2023-06-29 00:00 4153

Babies Bliss Introduces Comprehensive Fertility Wellness Programme to Enhance Reproductive Health and Conception Journey

SINGAPORE, June 28, 2023 /PRNewswire/ -- Babies Bliss, a Singapore-based fertility wellness centre, is proud to announce its innovative fertility wellness programme designed to support women in improving their reproductive health and preparing their bodies for conception. The comprehensive progra...

2023-06-28 18:44 3258

European Society of Hypertension Announces Comprehensive New Guidelines for the Management of Arterial Hypertension

MILAN, June 28, 2023 /PRNewswire/ -- The European Society of Hypertension (ESH), the leading hypertension society inEurope, released updated and expanded 2023 ESH Guidelines for the Management of Arterial Hypertension during three oral presentations atthe 32nd Annual European Meeting on Hypertens...

2023-06-28 18:00 9557

Lo.Li. Pharma International and its International Partners Achieve a New World Record to Raise Awareness About Innovative Options for Managing PCOS and Infertility

COPENHAGEN, Denmark, June 28, 2023 /PRNewswire/ -- The Society of Human Reproduction and Embryology (ESHRE) annual meeting witnessed a historic event as people from around the globe gathered both in person and online to set a new world record for the most people consuming a dose of inositol simul...

2023-06-28 17:25 3588

Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

SHANGHAI, June 28, 2023 /PRNewswire/ -- Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA),  has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of ensifentrine for the maintenance treatment of patients with chronic obstructi...

2023-06-28 17:07 6529

First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed

* After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discovered and AI-generated drug, has entered multi-regional Phase II clinical trials in the U.S andChina. * The first human patients were dosed with the drug. * This is a potentially first-in-class an...

2023-06-27 21:00 5765

TMRW Life Sciences Names Louis Villalba Chief Executive Officer

Seasoned Executive Appointed to Lead Fast-Growing Technology Company as It Signs 50 Fertility Clinics Representing Nearly 20% Market Share NEW YORK, June 27, 2023 /PRNewswire/ -- Today, TMRW Life Sciences, Inc. ("TMRW"), a fertility technology company automating the IVF lab, appointedLouis Villa...

2023-06-27 20:00 2474

Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership

SHANGHAI, June 27, 2023 /PRNewswire/ -- June 26th, 2023, Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics. As leaders in their respective...

2023-06-27 15:33 5421

Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy

SINGAPORE and GUANGZHOU, China, June 27, 2023 /PRNewswire/ -- 27 June 2023, Lion TCR, a clinical-stage T-cell immunotherapy company, is thrilled to announce the successful completion of itsUSD 40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Grou...

2023-06-27 08:30 5516

CStone announces GAVRETO® (pralsetinib) sNDA approval by China NMPA for first-line treatment of patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer

* The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer marks the third indication of GAVRETO in Mainland China, and the eleventh new drug application approval that CStone has obtained inGreater China overall. * In the ARROW study, GAVRETO had demonstrate...

2023-06-27 08:05 4595

New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC

MELBOURNE, Australia, June 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRC...

2023-06-27 03:51 3223

DentalMonitoring reinvents the scan experience

PARIS and AUSTIN, Texas, June 26, 2023 /PRNewswire/ -- DentalMonitoring announces their latest innovation, ScanAssist, the only AI-guided scan process available in orthodontics, designed to provide a fun, engaging patient experience, while also providing unprecedented photo quality for clinical ...

2023-06-26 23:43 3728

CXR-AID, Powered by Lunit, Nets Japan Nod for Reimbursement, Accelerating Market Expansion Opportunities

- Medical AI solutions, including CXR-AID, officially included in Japanese health insurance reimbursement as a management service fee of imaging diagnosis SEOUL, South Korea, June 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of cancer diagnostics solutions, today announced th...

2023-06-26 21:00 4325

Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture "Insighta" for Breakthrough Multi-Cancer Early Detection Screening

Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics which is supported by the InnoHK Initiative of the Innovati...

2023-06-26 08:45 4205

Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023

HANGZHOU and SHAOXING, China, June 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B (...

2023-06-26 08:10 4545
1 ... 235236237238239240241 ... 381

Week's Top Stories